The issue of reimbursement being not allowed for switching between JAK inhibitors in rheumatoid arthritis, which has been a pet peeve on site, will be resolved soon.

According to Dailypharm coverage, the health authorities decided to allow insurance reimbursement benefits for cross-dosing between JAK inhibitors in rheumatoid arthritis in October.

Currently, 4 drugs are prescribed for rheumatoid arthritis in Korea, including Pfizer Korea’s Zelanz (tofacitinib), Lilly's Olumiant (baricitinib), AbbVie's Rinvoq (upadacitinib), and Eisai Korea’s Jyseleca (filgotinib).

As such, the treatment landscape for rheumatoid arthritis is expected to improve significantly starting next